Collection of Blood From Patients With Prostate Cancer
To obtain blood samples from patients with prostate cancer for genotyping analyses.
All patients seen in the NCI prostate cancer clinic are eligible.
Patients with a prior diagnosis of prostate cancer will be evaluated in the Medical Oncology
Clinic, NCI. Blood samples may be collected at the initial visit or at follow-up visits.
Genomic DNA and white blood cells will each be extracted from these samples to be utilized
for genotyping and establishment of individual cell lines. Genetic variance will be
correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic
indicators (i.e. histological tumor grade). Healthy controls will not be compared and no
correlations will be made with prostate cancer susceptibility.
Time Perspective: Prospective
William D Figg, Pharm.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|